# The Leukemia and Lymphoma Society (LLS) T-cells in Blood Cancer and COVID-19

> **NCT04898985** · — · SUSPENDED · sponsor: **Larry Saltzman, MD** · enrollment: 1000 (estimated)

## Conditions studied

- Covid-19

## Interventions

- **DIAGNOSTIC_TEST:** ImmunoSEQ

## Key facts

- **NCT ID:** NCT04898985
- **Lead sponsor:** Larry Saltzman, MD
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** SUSPENDED
- **Start date:** 2021-05-20
- **Primary completion:** 2031-05-20
- **Final completion:** 2031-05-20
- **Target enrollment:** 1000 (ESTIMATED)
- **Why stopped:** Recruitment was completed for initial evaluation of T-cell response to early Covid-19
- **Last updated:** 2022-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04898985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04898985, "The Leukemia and Lymphoma Society (LLS) T-cells in Blood Cancer and COVID-19". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04898985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*